A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin LymphomaJesús G. Berdeja, Sagar Lonial, Neha Mehta–Shah et al.|Blood|2021Cited by 22
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MMSagar Lonial, Jesus Bardeja, Shambavi Richard et al.|Cancer Research|2022Cited by 11